CT-INDUSTRIAL-FLOW
18.10.2021 13:08:11 CEST | Business Wire | Press release
Leading industrial pumping solutions provider Industrial Flow Solutions ™, headquartered in New Haven, Conn., USA, announced today the agreement to acquire Clearwater Controls Ltd. ™, based in Glasgow, Scotland. Clearwater Controls offers a broad line of wastewater solutions, beginning with its leading deragging intelligent systems to solve specific pumping problems, to more advanced monitoring technology to optimize and manage entire water networks. Terms of the acquisition were not disclosed. Clearwater Controls will retain its company name and brand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005200/en/
Clearwater Controls is known worldwide for the DERAGGER ™+ line of intelligent deragging control systems. The company is bringing the Internet of Things (IoT) to industry sectors with its newest innovation: cloud-based data analytics and management for improved monitoring of water networks.
Clearwater Controls’ solutions allow engineers and operators to analyze and create baseline data on the performance of their pump networks in real time to optimize operations, identify problems, perform money-saving predictive maintenance, and avoid potentially harmful and costly environmental impacts. These smart interventions will transform the industry from its historic reactive approach to a predictive asset management model.
Incorporating Clearwater Controls’ DERAGGER PRO pump station controller across its brands will bring intelligent efficiency to nearly all product lines of Industrial Flow Solutions, particularly the innovative OverWatch™ Direct In-Line Pumping System platform. Clearwater Controls’ complementary products and technology will provide greater value to customers seeking to reduce startup time, strengthen reliability and provide real-time cloud-based data.
“As technology and smart data bring new changes to the water industry, this acquisition will establish Industrial Flow Solutions and Clearwater Controls as leaders in the new digital revolution,” said John Wilson, President of Industrial Flow Solutions. “This new partnership supports our combined missions to transform any industry that relies on high usage of water and the need for treatment,“ he added.
Wilson expects a dramatic increase in Clearwater Controls’ business as it develops a greater product range for the DERAGGER+ and expands its global customer base.
“This acquisition is of mutual benefit to both companies, making each uniquely more competitive. We have common values of being customer focused, highly responsive, innovative, collaborative, supportive, and ambitious,” Wilson said. “We will provide Clearwater Controls with resources and expertise to strengthen its business overall. Reciprocally, Clearwater Controls’ unique and agnostic control solutions open a huge opportunity for Industrial Flow Solutions to access a worldwide market,” Wilson added.
“Clearwater Controls is taking the lead in seizing the groundswell of interest and momentum around intelligent monitoring and management of wastewater networks,” said Simon Crompton, Managing Director, Clearwater Controls. “Our partnership with Industrial Flow Solutions provides us with a greater footprint to advance pumping technology worldwide,” said Crompton.
About Industrial Flow Solutions
Industrial Flow Solutions specializes in the design, manufacturing, sales and service of pumping and fluid management solutions for harsh, rugged environments. With OverWatch™ direct in-line pump systems, BJM Pumps® products and Stancor® Pumps and Controls, the company offers a comprehensive portfolio of submersible and direct in-line pumps and controls ideal for industrial, commercial and municipal wastewater applications. Industrial Flow Solutions, headquartered in New Haven, Conn., is a portfolio company of May River Capital , a Chicago-based private-equity firm focused on lower middle-market industrial growth companies. For more information, please visit https://flowsolutions.com .
About Clearwater Controls Ltd.
Clearwater Controls launched in 2009 as the research and development division of ID Systems. The company has conceived, developed, and delivered a suite of intelligent pump monitoring and anti-ragging solutions, built around its unique and patented technology. Based in Glasgow, Scotland, United Kingdom, with a rapidly expanding operation in the United States, Clearwater Controls delivers solutions to clients across the UK, Ireland, Continental Europe, and North America. For more information, please visit https://clearwatercontrols.co.uk .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005200/en/
Link:
Social Media:
https://www.facebook.com/Industrial-Flow-Solutions-102601071895549
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom